~ Buy the TACLONEX (betamethasone dipropionate; calcipotriene) Drug Profile, 2024 PDF Report in the Report Store ~

TACLONEX Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Taclonex, and when can generic versions of Taclonex launch?

Taclonex is a drug marketed by Leo Pharma As and is included in two NDAs.

The generic ingredient in TACLONEX is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TACLONEX?
What are the global sales for TACLONEX?
What is Average Wholesale Price for TACLONEX?

Summary for TACLONEX

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	13
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TACLONEX
What excipients (inactive ingredients) are in TACLONEX?	TACLONEX excipients list
DailyMed Link:	TACLONEX at DailyMed

Drug patent expirations by year for TACLONEX

Recent Clinical Trials for TACLONEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Taro Pharmaceuticals USA	Phase 1
Glenmark Pharmaceuticals Ltd. India	Phase 3
Tolmar Inc.	Phase 1

See all TACLONEX clinical trials

Pharmacology for TACLONEX

Drug Class	Corticosteroid Vitamin D Analog
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Paragraph IV (Patent) Challenges for TACLONEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TACLONEX	Ointment	betamethasone dipropionate; calcipotriene	0.005%/0.064%	021852	1	2010-03-31

US Patents and Regulatory Information for TACLONEX

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	OINTMENT;TOPICAL	021852-001	Jan 9, 2006	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	SUSPENSION;TOPICAL	022185-001	May 9, 2008	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for TACLONEX

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	SUSPENSION;TOPICAL	022185-001	May 9, 2008	⤷ Sign Up	⤷ Sign Up
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	SUSPENSION;TOPICAL	022185-001	May 9, 2008	⤷ Sign Up	⤷ Sign Up
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	OINTMENT;TOPICAL	021852-001	Jan 9, 2006	⤷ Sign Up	⤷ Sign Up
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	SUSPENSION;TOPICAL	022185-001	May 9, 2008	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for TACLONEX

See the table below for patents covering TACLONEX around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	0064450		⤷ Sign Up
Australia	6196186		⤷ Sign Up
Canada	2423930	COMPOSITION TOPIQUE CONTENANT AU MOINS UNE VITAMINE D OU UN ANALOGUE DE VITAMINE D ET AU MOINS UN CORTICOSTEROIDE (TOPICAL COMPOSITION CONTAINING AT LEAST ONE VITAMIN D OR ONEVITAMIN D ANALOGUE AND AT LEAST ONE CORTICOSTEROID)	⤷ Sign Up
Russian Federation	2271810	КОМПОЗИЦИИ МЕСТНОГО ПРИМЕНЕНИЯ, СОДЕРЖАЩИЕ, ПО МЕНЬШЕЙ МЕРЕ, ОДИН ВИТАМИН D ИЛИ ОДИН АНАЛОГ ВИТАМИНА D И, ПО МЕНЬШЕЙ МЕРЕ, ОДИН КОРТИКОСТЕРОИД (COMPOSITIONS FOR TOPICAL USING COMPRISING AT LEAST ONE VITAMIN D OR ONE VITAMIN D ANALOG AND AT LEAST ONE CORTICOSTEROID)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration